PD98059

Catalog No.S1177

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Price Stock Quantity  
USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD98059 Chemical Structure

PD98059 Chemical Structure
Molecular Weight: 267.28

Validation & Quality Control

Cited by 48 publications:

8 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Targets MEK1 [1]
(Cell-free assay)
IC50 2 μM
In vitro PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H1355NEnROVNHfW6ldHnvckBCe3OjeR?=Moe0NlUh|ryPNWLuNlBOOSCqMXXicJVvfHNidHjlJGJc[V2SLXnu[JVk\WRiaX7jdoVie2ViaX6gdIhwe3Cqbz3DbIsyKGGwZDDwbI9{eGixLVXST{BmgHC{ZYPzbY9vMmGwNlU4PjlzOEG=
MCF-7 M{Ds[GZ2dmO2aX;uJGF{e2G7NIHlfGUyOCEQvF2=NFPR[XgyKGh?MmTMbY5pcWKrdIOgTWwuOThvZX7oZY5k\WRiY3XscEBucWe{YYTpc44>MmPvNlU4OjdyMUG=
HepG2 NXnmfoE2TnWwY4Tpc44hSXO|YYm=MX2xNEDPxE1?NW[3elV4PSCqNITmc4tjdG:la4OgdIhwe3Cqb4L5cIF1\WRiTVHQT5MhcW6mdXPl[EBjgSCneH;n[Y5wfXNiVFfGMe6zOQ>?NGL1UIkzPTV4MES4PC=>
HepG2 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTofph5OjBizszNNWHiZ|dXOjRiaB?=M{jvVZN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBidmRiaX72ZZNqd25?M3PYeVI2PTZyNEi4
MDA-MB-231MWjGeY5kfGmxbjDBd5NigQ>?NHjR[HgzPSEQvF2=MVuyMVMhcA>?NXXObZRt\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?=NUTJWHlrOjV3NUW4O|U>
SW480NVrkWm9ZTnWwY4Tpc44hSXO|YYm=MkLSNlDDqM7:TR?=Mle3NeKhcA>?MX3y[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=>MXGyOVQ1PzhzNh?=
HCT-15NV;JN25kTnWwY4Tpc44hSXO|YYm=NHvBcWEyKGh?NGX6cWtifHSnboXheIV{KFCJRUKtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsyqB?Mo\HNlU1OzF2MkW=
HCT-15MX7BdI9xfG:|aYOgRZN{[Xl?NIXSOWYyKGh?NV3xbFND[WKxbHnzbIV{KHSqZTDwdo91\WO2aY\lJIVn\mWldIOgc4YhWEeHMtMgZYdicW6|dDDjeZJkfW2rbj3pcoR2[2WmIHHwc5B1d3Orcx?=Mk\ONlU1OzF2MkW=
786-OMY\BdI9xfG:|aYOgRZN{[Xl?NXXWbZZrPTEEoN88US=>Mn7KNlQhcA>?MnLIdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO=NFnENIYzPDVyOES3Oi=>
A498MYXBdI9xfG:|aYOgRZN{[Xl?MmDKOVDDqM7:TR?=M4DXWVI1KGh?MV3wc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?=NFjEPIwzPDVyOES3Oi=>
NHBEMXLGeY5kfGmxbjDBd5NigQ>?NF\IUm4zNzJyIN88US=>MV[yJIg>NGjhUm9ifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC|ZXPy[ZRqd25?NFf6U2YzPDR5OUWyOi=>
A375MlzvR4VtdCCLbo\hd4lwdiCDc4PhfS=>M1H1flEx6oDVMkCgxtVOM1PUO|I1KGh?NHfQcY9z\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?NFHSO5QzPDR4NkCzOi=>
HBMECNYTtVWxCTnWwY4Tpc44hSXO|YYm=NW\ybHUyOTBizszNMVSxJIg>MVLicI9kc3NiVlXHSk1qdmS3Y3XkJGVxcEF{IHX4dJJme3Orb36=MkH6NlQ1PTh7OEK=
HPAEpiCs Mn;iSpVv[3Srb36gRZN{[Xl?M33KXFMxKM7:TR?=M{HMSlEhcA>?NXnwRYNDcW6qaXLpeJMhXE6ILd8xJJN1cW23bHH0[YQheDR{L4C0OEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?MVeyOFQ1OTh5MB?=
BeWoNIfMR|BHfW6ldHnvckBCe3OjeR?=MkHBNVDDqM7:TR?=NUXXb2x4OiCqMUXpcohq[mm2czDFVmsyNzJ?MX:yOFQ{Ozh2Nh?=
PC3 NIXmVZRCeG:ydH;zbZMhSXO|YYm=M1fLZ|UxKM7:TR?=NHraN4MxNjViaB?=NX;WNHNbcW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:KhMX[yOFQzPDh6OR?=
HGC-27Ml:4RZBweHSxc3nzJGF{e2G7NILGUowyKML3TR?=MkezNUBpMYHzeZBxemW|c3XzJHJCTDByMTDwcJV{KE2NLUKyNFYucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{NWXCNm0zOjR2MU[zOFk>
MCF-7MnPBSpVv[3Srb36gRZN{[Xl?NUjCdHBvOTEEoN88US=>M3[xSFExNzNyIH3pci=>NUHFXo1iemWmdXPld{B1cGViVWTQMYRmeGWwZHXueEBGWkticHjvd5Bpd3K7bHH0bY9vNFzVTnEzPDN7MEixPS=>
HUVECsNFHhOG1HfW6ldHnvckBCe3OjeR?=NWTuOoJSOTEEoN88US=>M2fuR|EhcA>?NH3aRnJqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG|ZR?=NV:zcFVoOjR|OEWxNFk>
HeLaNFG3VWdHfW6ldHnvckBCe3OjeR?=M1r4dFUxKM7:TR?=M1vEZlAvPSCqNYnIRY93[myxY3vzJHRTYC1zIH71Z4xm[XJibXnndoF1cW:wIHHu[EBVYE6LUDDkc5dvNXKnZ4XsZZRqd25?NUX6bXpvOjR|N{[4Nlc>
HL-60 NIHpW25HfW6ldHnvckBCe3OjeR?=NWnUV29JOTBxMkCg{txONETUemQyKGh?MnjpbY5pcWKrdIOgeIhmyqCQLjDjbIlv\W6|aYPlfJRz[WO2wrDpcoR2[2WmIHTp[oZmemWwdHnheIlwdiCrboTvJIdz[W63bH;jfZRmew>?MkXBNlQ{PTdyMkC=
HL-60NVTP[nZmTnWwY4Tpc44hSXO|YYm=NESxeHgzKML3TR?=NF70V4YyPiCqMofUSG1UVw>?NUDRPWplcW6qaXLpeJMhfGinIHHzd49kcWG2aX;uJI9nKHCVNkKxJHJi\i1zIHHu[EBPTkGWY{OsJIFv\CC2aHWgVmEucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhdnWlbHXhdkBPTkGWY{O=MWWyOFM{ODB4OB?=
HEK 293MX;GeY5kfGmxbjDBd5NigQ>?Mon3NVAh|ryPM2i2elUhcA>?MofISG1UVw>?MV\pcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36=MU[yOFMzPDN4Nh?=
HEK 293MXTGeY5kfGmxbjDBd5NigQ>?MX2xNEDPxE1?NF7OWoE2KGh?M32ybWROW09?Mnnwd5VxeHKnc4Pld{B1cGViQ2LUJIFkfGm4aYT5MU[yOFMzPDN4Nh?=
SW480Mn3NSpVv[3Srb36gRZN{[Xl?NUfre5ZuOTBizszNNInNZ|MzOCCqMne3SG1UVw>?NF7VR5l{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>MVWyOFMzPDN4Nh?=
HCSMCsMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV2xNEDPxE1?MXqyOEBpMWPicI9kc3NiRlHCVFQucW6mdXPl[EBJS0GVTVOgdJJwdGmoZYLheIlwdg>?MWWyOFMyOjN6MR?=
PANC-1MUfGeY5kfGmxbjDBd5NigQ>?MWeyNEDPxE1?NY\1U2Z{PDhiaB?=MoPNbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB?NV3rR4VlOjR{OUSxN|M>
A549Mlm5SpVv[3Srb36gRZN{[Xl?MVqzNEDPxE1?NGDhdWMxNjViaB?=M{TJd2ROW09?M2DMfIlvcGmkaYTzJJRp\SC2aILvcYJqdi2rbnT1Z4VlKEmOLUivR3hEVDhvTIXjJIFkfGm4aYT5MmDCNlQzPzd4OU[=
A549MnfySpVv[3Srb36gRZN{[Xl?NF;TZmo{OCEQvF2=M3vwTFAvPSCqNHXRUGVFVVORNYjLb3FKcW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ|NdMgdIhwe3Cqb4L5cIF1cW:wM4HSRVI1Ojd5Nkm2
MC-3MWTBdI9xfG:|aYOgRZN{[Xl?MVOxNEDPxE1?NH3XVFAzPCCqNIe5eXVxd3SnboTpZZRm\CCPRWPDMYlv\HWlZXSgZZBweHSxc3nzJIlvKCClZXzsdy=>M3;VT|I1OjdyNUKz
Raji M{PjbWZ2dmO2aX;uJGF{e2G7NUGxR21ZOTBizszNMXGxJIg>NEHtOnZjdG:la4OgbJNDSU[IIHnu[JVk\WRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvci=>NUPsW3N5OjR{Nkm2N|A>
Raji MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUP4dnl2OTBizszNMWSxJIg>MnrJbY5pcWKrdIOgeIhmKGKjc3HsJI9zKGi|QlHGSk1{fGmvdXzheIVlKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5NWPndHc4OjR{Nkm2N|A>
HT29NFjzToRHfW6ldHnvckBCe3OjeR?=NUnROYhUOTBizszNMoHYNkBpNWnwOlRYcW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:|cHjvdplt[XSrb36=NXHJSndMOjR{NkWyPVM>
HepG2M{\MOWFxd3C2b4Ppd{BCe3OjeR?=M4f2XFIxKM7:TR?=MmfyNlQhcA>?MUfpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>M3joOFI1OjR5OUC5
HepG2NF3NUIxHfW6ldHnvckBCe3OjeR?=M4\GVVIxKM7:TR?=NIq1blgzKGh?NVvLRWZE\W6qYX7j[ZMhXkJzLXnu[JVk\WRiRl;YU|NiKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fS=>NHL4S40zPDJ2N{mwPS=>
TE4MWXGeY5kfGmxbjDBd5NigQ>?MXOyNE82OC9zMECg{txOM2\lb|Q5KGh?M3TvS2ROW09?NUTrVpZicW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=Mn3DNlQzPDRyMkO=
TE1NVywOYdyTnWwY4Tpc44hSXO|YYm=MlzuNlAwPTBxMUCwJO69VQ>?NFnhZ|k1QCCqMUfEUXNQM4HqTIlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?NFm4Z|MzPDJ2NECyNy=>
KYSE30M2XkUGZ2dmO2aX;uJGF{e2G7NUfmUoM2OjBxNUCvNVAxKM7:TR?=MXe0PEBpMX\EUXNQMkDibY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?Mn3YNlQzPDRyMkO=
TE1NWXadmg6TnWwY4Tpc44hSXO|YYm=M{jYdVUxKM7:TR?=M1XuPFQ5KGh?M13neWROW09?NVL2R2xUfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm=NEnMTFAzPDJ2NECyNy=>
TE3NFjOfHpHfW6ldHnvckBCe3OjeR?=MWO1NEDPxE1?Ml\6OFghcA>?M3vRXWROW09?MmLoeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?Mo[zNlQzPDRyMkO=
TE4M37MeWZ2dmO2aX;uJGF{e2G7M2DlWVUxKM7:TR?=MUG0PEBpNWXaV3RqTE2VTx?=NIPocWp2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?=MnPSNlQzPDRyMkO=
TE5NET0VFhHfW6ldHnvckBCe3OjeR?=MVS1NEDPxE1?M1nWdFQ5KGh?NVjuVoZCTE2VTx?=MYT1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?MXqyOFI1PDB{Mx?=
KYSE30MmDRSpVv[3Srb36gRZN{[Xl?M2jSb|UxKM7:TR?=MX:0PEBpNX7XfYpLTE2VTx?=NH3XSY92eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?=M3\rZ|I1OjR2MEKz
MKN7MV\GeY5kfGmxbjDBd5NigQ>?MkHjOVAh|ryPMlL6OFghcA>?NVnDSZF{TE2VTx?=M2HuTolv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=NIDEcJczPDJ2NECyNy=>
OE19NHH2WoZHfW6ldHnvckBCe3OjeR?=Mn;OOVAh|ryPNGLzRnI1QCCqMlvWSG1UVw>?M2T2[Ylv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=M4fhXFI1OjR2MEKz
KATOIII NWLwXmxVTnWwY4Tpc44hSXO|YYm=M4fW[VUxKM7:TR?=MmnrOFghcA>?M{[5[2ROW09?M2P0UYlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=MnfpNlQzPDRyMkO=
NCI-N87 MVvGeY5kfGmxbjDBd5NigQ>?NWHyN3FSPTBizszNMlfsOFghcA>?MoK2SG1UVw>?M{jOVIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=MXOyOFI1PDB{Mx?=
NUGC3NGL1XnRHfW6ldHnvckBCe3OjeR?=MUS1NEDPxE1?Mle4OFghcA>?M4fyeGROW09?NF3ieYhqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXzM4DxO|I1OjR2MEKz
NUGC2M4HKNmZ2dmO2aX;uJGF{e2G7M{\zWFUxKM7:TR?=MmrROFghcA>?NUHiWoJpTE2VTx?=MkTMbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=M4TkZlI1OjR2MEKz
SGC-7901 NI\jTWxCeG:ydH;zbZMhSXO|YYm=M{HwXFIxKM7:TR?=MXyyOEBpMmLNbY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{M2DKNVI1OjRzM{Wx
MG-63NYKzXZBLTnWwY4Tpc44hSXO|YYm=NUTXbGlYOjBizszNNFrsXnkxNjViaB?=NUDNVHRI[myxY3vzJJRp\SCFSD3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKEWOS{GgdJJwfGWrbjDlfJBz\XO|aX;uM{LiXVI1OjN7NkSw
ARPE-19M1K0NmZ2dmO2aX;uJGF{e2G7NFL6RWwzOCEQvF2=NHjaZngxNjViaB?=Ml;0bY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0MWGyOFIzPzlzOB?=
CRL-2302M3nIb2Z2dmO2aX;uJGF{e2G7M{fUdlIxKM7:TR?=NFXUc20xNjViaB?=MWrpcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S=MVOyOFIzPzlzOB?=
MCF-7M{PYdmZ2dmO2aX;uJGF{e2G7Mo\xNlAh|ryPMkf3NUBpMVHhZo9tcXOqZYOg[ZhxemW|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSnNX70PGl1OjR{MU[yPFk>
MCF-7MomyRZBweHSxc3nzJGF{e2G7MoGzNlAh|ryPMly1NUBpNFXjNIZqdmO{ZXHz[ZMh[2G|cHHz[U06KGWweont[UBi[3Srdnn0fS=>M4\FWlI1OjF4Mki5
DLD-1 M37YR2Z2dmO2aX;uJGF{e2G7NUS0RmgxOjEEoN88US=>NI\N[|I1QCCqMnLhdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTDMln3NlQzOTF3OEG=
HT-29M4rDO2Z2dmO2aX;uJGF{e2G7NEfQdoczOMLizszNNGHSc4c1QCCqM{LNVJJm\HWlZYOgeIhmKEKQSWCzJIV5eHKnc4Ppc44heHKnLYTy[YF1\WRid3n0bEA2NWG8YT3kRy=>MknpNlQzOTF3OEG=
7402NUHBWIhISXCxcITvd4l{KEG|c3H5NX:3ZnJZOzBizszNM122NVUh\A>?MWTk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uMW[yOFIyOTJ3Mx?=
7721MkTsRZBweHSxc3nzJGF{e2G7M2Py[VMxKM7:TR?=MmixOUBlMlzz[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>MViyOFIyOTJ3Mx?=
SGC7901 M3KwV2Fxd3C2b4Ppd{BCe3OjeR?=M{\INlUxyqEQvF2=MnnVNlQwPDhxN{KgbC=>NHLZXZVFVVORNVzyeY9DcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDKRWszKHOqUl7BNXHtTIZPOjRzN{iyOFA>
SMMC7721MUPGeY5kfGmxbjDBd5NigQ>?MofMNlUwPTBizszNM1zzSlI1KGh?M3fvVpN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM|LDqA>?NYnWeGJSOjRzNkiwOVY>
MCF-7MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vrW|ExKM7:TR?=NEDVNII1QGh?Mn[0SG1UVw>?MVTy[ZZmenOnczDCUmYucW6mdXPl[EBk\WyuIHP5Z4xmKGG{cnXzeC=>M2L5dFI1OTZ|NEC0
Caco-2M2roS2Z2dmO2aX;uJGF{e2G7MYq1NOKh|ryPMlPqOFhpNXPXS5B4TE2VTx?=MWDlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW|wrDjc{11emWjdHXkJJdqfGhiRHX4MVSyOFE3OTZ7NR?=
HAECsMoLlSpVv[3Srb36gRZN{[Xl?M{Dpe|ExKM7:TR?=MUKxJIg>MXRCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>?MUmyOFE{PDZ3Nx?=
Ca9-22NH3GXZZHfW6ldHnvckBCe3OjeR?=NH75O28{KM7:TR?=M3fzb|EhcA>?NVHwN5VP[WKxbHnzbIV{KHSqZTDhZoltcXS7IH;mJGhjWiC2bzDpcoR2[2ViSVytPEBxem:mdXP0bY9vM3nM[|I1OTJ4NUOy
Ca9-22MXTGeY5kfGmxbjDBd5NigQ>?NYfhPHRjOyEQvF2=NXrMe3FPOS9{IHi=MkXJdoVlfWOnczDIZnIucW6mdXPl[EBCXEZvMjDwbI9{eGixconsZZRqd25?NXjRelFIOjRzMk[1N|I>
AGSNIKzWYJHfW6ldHnvckBCe3OjeR?=M2jaeVExKM7:TdMgM{PVc|AvPSCqNIXtfWxqdmirYnn0d{B1cGVidYDy[Yd2dGG2aX;uJI9nKHSqZTDJUE05KGenbnW=MWiyOFExPjF4Nh?=
Caco-2 MUnBdI9xfG:|aYOgRZN{[Xl?MVexNOKh|ryPM{izNlI1yqCqNHzvW|dl\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[XNVHLXVBlOjRyOUW4OlM>
HCT-8MnP4RZBweHSxc3nzJGF{e2G7NF3KUosyOMLizszNNIfzVW4zPMLiaB?=MnnG[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>?NED2cWIzPDB7NUi2Ny=>
A549NV;3RWFoTnWwY4Tpc44hSXO|YYm=MWK1NOKh|ryPM4DK[|IhcA>?MmrBZoxw[2u|IFXST{BxcG:|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7RNUW0dVlZOjRyNke3Nlc>
HPMCMmW1SpVv[3Srb36gRZN{[Xl?NGfqcFcyOMLizszNMXe0PEBpMoD3doV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM>MViyOFA1Ojh|OB?=
HPMCMVvBdI9xfG:|aYOgRZN{[Xl?M2LWelExyqEQvF2=NG\aTW8zPMLiaB?=NIPqTodz\X[ncoPld{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KEiJUFTTNXXP[VV[OjRyNEK4N|g>
MGC803 MX7BdI9xfG:|aYOgRZN{[Xl?MUeyNOKh|ryPNGHBNIwyKGh?M4TYTolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=MVKyOFAzPzd3MB?=
SGC7901M3P2O2Fxd3C2b4Ppd{BCe3OjeR?=Ml3kNlDDqM7:TR?=MYSxJIg>M3r1VYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=NEL4XI0zPDB{N{e1NC=>
COLO205NVTYRVVmSXCxcITvd4l{KEG|c3H5M{DBWFExNzJyL{SwJO69VQ>?NIT4O2UzPCCqNV\le3pWcW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>?NX;ININYOjRyMUmxNFg>
G292 M3G5d2Fxd3C2b4Ppd{BCe3OjeR?=MknWN|DDqM7:TR?=NVLEbWdoOiCqMWDy[ZN1d3KnczDjZZB{[WmlaX6tbY5lfWOnZDDj[YxtKGSnYYToMWqyOFAyOjl|MB?=
BxPC-3NFXj[FdHfW6ldHnvckBCe3OjeR?=MkTHNVAh|ryPwrC=MVe2JIg>MXrpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36=MnzhNlM6PzN5MUC=
HPAF-IIMnrnSpVv[3Srb36gRZN{[Xl?NF7NOGwyOCEQvF5CpC=>NV;heJBZPiCqNVK0WIROcW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9vNHm5SVAzOzl5M{exNC=>
HL-60MlfyRZBweHSxc3nzJGF{e2G7NV6wSFNxPTEEoN88US=>MmTKNUBpMoP4doV{[3WnczDCRVE1PSCvZXTpZZRm\CCjcH;weI9{cXN?MWOyN|k1QDd3MR?=
HepG2MYrGeY5kfGmxbjDBd5NigQ>?NGPIV|A1OCEQvF2=NFjvNIw3NzF{IHi=M1WzbolvcGmkaYTzJJRp\SCrbnPy[YF{\SCxZjDwMWVTUzFiYX7kJJAu[y2MdX6gdJJwfGWrbjDlfJBz\XO|aX;uJIJ6KFCOMXKyN|k1Ojh3MR?=
HUVECsMlnDSpVv[3Srb36gRZN{[Xl?NWH2SY9POjVizszNNUTNXmFMOSCqNXHIe5N3cW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36=MWqyN|kxOTByOB?=
LNCaP NYL3dm1UTnWwY4Tpc44hSXO|YYm=MYixNEDPxE4EoB?=M{XuXFEhcA>?NEPVfZhl\WO{ZXHz[ZMhfGinIFXHSkB2eHKnZ4XsZZRm\CCyLWnCMVE>Mmq3NlM5Ozh|MUi=
HL60 Mme2SpVv[3Srb36gRZN{[Xl?MmHDNlDDqM7:TR?=M4q5O|czKGh?MU\EUXNQM3vnXYlvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36=NYCw[|BVOjN6MkW1PFU>
NB4 M{LXW2Z2dmO2aX;uJGF{e2G7MonWNVAh|ryPwrC=MXq3NkBpMWLEUXNQMYPpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:wM1j4NVI{QDJ3NUi1
EPOR/CR3NH\yT|FHfW6ldHnvckBCe3OjeR?=MUO1NOKh|ryPM4DV[VMhcA>?NI\ndpRz\WS3Y3XzJGVRVyCjbnSvc5IhUUxvMz3pcoR2[2WmIITo[UB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb39CpC=>Mn7jNlM5OjB5M{G=
HUASMCsM{i0eWZ2dmO2aX;uJGF{e2G7MlvhNVAh|ryPwrC=MkHqNlQhcA>?M4\PdYRqdWmwaYPo[ZMhSW6pIFnJMYNifXOnZDDTU2NUOyCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd28EoB?=MV2yN|gyPjR4OB?=
HUASMCsMojxSpVv[3Srb36gRZN{[Xl?NVSzdmJTOTBizszNxsA>MWiyOEBpNGntTlJqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXsMlm3NlM5OTZ2Nki=
SGC7901MnLRSpVv[3Srb36gRZN{[Xl?NGnGN4EyOCEQvF5CpC=>NVjtSopkOjRiaB?=NEfRUYdqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ?NHjBV2YzOzd7MkW4PC=>
MKN45NYn3Wm9LTnWwY4Tpc44hSXO|YYm=NX\jZ3BSOTBizszNxsA>NVTHdWVDOjRiaB?=MUDpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I>NGPofXkzOzd7MkW4PC=>
SGC7901M4LQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XpNlExKM7:TdMgM4PvVFI1NzR6L{eyJIg>NIfWeIFqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?=M13HclI{Pzl{NUi4
MKN45M4PwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVmxNEDPxE4EoB?=NVf2XVJROjRxNEivO|IhcA>?M3jvOolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCWM3;JVVI{Pzl{NUi4
SGC7901MkLHRZBweHSxc3nzJGF{e2G7M4fVTFExKM7:TdMgMorMNlQhcA>?NX\JVZBHcW6lcnXhd4V{KHSqZTDERXBVNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO=M3rmSFI{Pzl{NUi4
MKN45NY\5O3R2SXCxcITvd4l{KEG|c3H5M1HkXFExKM7:TdMgNHjNW3UzPCCqMUDpcoNz\WG|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?NHvidXozOzd7MkW4PC=>
BxPC-3 cellsM2XRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\VNlDDqM7:TR?=MoDsNE42KGh?MnXFbY5pcWKrdIOgWmVITi2DLYLl[5Vt[XSnZDDIWXZGSyCpcn;3eIgh[W6mIIT1ZoUh\m:{bXH0bY9vKGmwZIXj[YQh[nliUFHSMVIhSVB?NIfPe2YzOzd4NEC0Oi=>
NB4 NUHKS3VySXCxcITvd4l{KEG|c3H5MVyxNE8zOC94MDFOwG0>M4frVFEvPSCqNWLqem91TE2VTx?=NInLOW9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTl[EB4cXSqIGDhZ4xqfGG6ZXy=MUmyN|c{PTV2MR?=
HepG2 NF;sR45HfW6ldHnvckBCe3OjeR?=MnixNlDDqM7:TR?=M1Pnb|I1KGh?Ml[wbY5pcWKrdIOgeIhmKEiRLUGgdJJwfGWrbjDlfJBz\XO|aX;uJINwNXS{ZXH0[YQhf2m2aDDt[ZRnd3KvaX6=MlL6NlM4ODd4MEm=
HUVECsMYHBdI9xfG:|aYOgRZN{[Xl?MXuyM|Qh|ryPM33vTFI1NzR6IHi=MVjpcoR2[2W|IHPlcIwh\GWjdHi=M{TjO|I{PzB5NUKw
KG-1 NVnLWZBLSXCxcITvd4l{KEG|c3H5NXvnVlFwOjEEoN88US=>NEWxR2EyOiCqM3;CeoVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgV|E>NWr4bHVYOjN5ME[2PVE>
AML 1#M2fX[2Fxd3C2b4Ppd{BCe3OjeR?=MoS0NlDDqM7:TR?=MV6xNkBpNH:2cXVmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMyNFPmRVIzOzdyNk[5NS=>
A2780 NInnWYJHfW6ldHnvckBCe3OjeR?=MYSyNOKh|ryPM3XvPFEhcA>?NEnpdpdjdG:la4OgSHRETC2rbnT1Z4VlKESUNTDlfJBz\XO|aX;uMofXNlM3QTZ6NkK=

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]
Features Does not inhibit c-Raf phosphorylated MEK1.

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro MEK-inhibitory activity Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.

Cell Assay:

[1]

Cell lines K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
Concentrations Dissolved in DMSO, final concentrations ~100 μM
Incubation Time 3 dyas, or 7-10 days
Method

For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.

Animal Study:

[7]

Animal Models Male Sprague–Dawley rats with acute pancreatitis
Formulation Dissolved in DMSO, and diluted in saline
Dosages 10 mg/kg
Administration Injection i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Dudley DT, et al. Proc Natl Acad Sci U S A, 1995, 92(17), 7686-7689.

[2] Alessi DR, et al. J Biol Chem, 1995, 270(46), 27489-27494.

view more

Chemical Information

Download PD98059 SDF
Molecular Weight (MW) 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL warming (52.37 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one

Frequently Asked Questions

  • Question 1
    How to formulate this inhibitor for i.p. injection?

    Answer: You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD184352 (CI-1040)

    PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

    Features:First MEK inhibitor to begin clinical development.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us